kinidin durules
astrazeneca uk limited - quinidine sulfate dihydrate - tablets - 200 milligram
kinidin durules 200 milligram tablets
astrazeneca uk limited - quinidine sulfate dihydrate - tablets - 200 milligram
kinidine 250mg durettes
waymade healthcare plc - quinidine bisulfate - modified-release tablet - 250mg
skinidine 75 mg/ml (7.5% w/v) cleansing solution
transcend phils., inc. - povidone iodine - cleansing solution - 75 mg/ml (7.5% w/v)
skinidine 75 mg/ml (7.5% w/v) cleansing solution
transcend phils., inc. - povidone iodine - cleansing solution - 75 mg/ml (7.5% w/v)
skinidine 100 mg/ml (10% w/v) topical solution
transcend phils., inc.; importer: n/a; distributor: n/a - povidone-iodine - topical solution - 100 mg/ml (10% w/v)
skinidine 4% w/v solution (feminine wash)
transcend phils., inc. - povidone-iodine - solution (feminine wash) - 4% w/v
kinidin durules
astrazeneca limited - quinidine bisulfate tetrahydrate 250mg equivalent to 200 mg quinidine sulphate; - modified release tablet - 200 mg - active: quinidine bisulfate tetrahydrate 250mg equivalent to 200 mg quinidine sulphate excipient: ethanol hard paraffin hypromellose macrogol 6000 magnesium stearate polyvinyl acetate polyvinyl chloride purified water titanium dioxide
kinidin 250mg durules
astrazeneca uk ltd - quinidine bisulfate - modified-release tablet - 250mg
lopinavir/ritonavir mylan
mylan s.a.s. - lopinavir/ritonavir - hiv infections - antivirals for systemic use, - lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infected adults, adolescents and children above the age of 2 years.the choice of lopinavir/ritonavir to treat protease inhibitor experienced hiv-1 infected patients should be based on individual viral resistance testing and treatment history of patients.